According to the Canadian Cancer Society, rare cancers make up around 20 percent of new cancer cases in Canada. Learn how the Ontario Institute for Cancer Research and Calgary-based Providence Therapeutics are harnessing mRNA technology to advance treatments for rare cancers and other conditions.